高强度聚焦超声治疗有症状良性甲状腺结节:一项前瞻性研究
这项前瞻性研究将有症状良性甲状腺结节患者分为超声引导高强度聚焦超声(HIFU)消融组(22例)和主动监测组(22例),评估12个月疗效。HIFU组12个月结节体积平均缩小68.87%±15.27%,监测组为-2.11%±6.29%(P>.05);消融前结节体积是消融成功的唯一决定因素(OR 1.877,95%CI 1.085-3.249,P=.024)。HIFU组12个月时肿胀感更轻、压迫症状评分更低、躯体综合评分更高。
要点
- HIFU组12个月结节体积平均缩小68.87%±15.27%,监测组为-2.11%±6.29%(P>.05)。
- 消融前结节体积是消融成功的唯一决定因素(OR 1.877,95%CI 1.085-3.249,P=.024)。
- HIFU组12个月时压迫症状评分更低、躯体综合评分更高(P=.006)。
核心结论
- 超声引导HIFU消融有症状良性甲状腺结节不仅引起结节显著缩小,还在12个月内改善了压迫症状评分和健康相关生活质量。
诊断标准与关键数值
- 消融成功定义为结节体积缩小大于50%;HIFU组12个月体积缩小68.87%±15.27%(范围47.35%-94.89%,P<.001),监测组-2.11%±6.29%(范围-15.64%至12.70%,P>.05)。
临床应用与阅片要点
- 消融前结节体积是消融成功的唯一决定因素(OR 1.877,95%CI 1.085-3.249,P=.024)。
- HIFU组12个月时肿胀感更轻(P<.001)、压迫症状评分更低(P<.001)、躯体综合评分更高(P=.006)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate first-year efficacy and changes in pressure symptoms and health-related quality of life (HRQOL) after ultrasonographically (US) guided high-intensity focused ultrasound (HIFU) ablation of symptomatic benign thyroid nodules. Materials and Methods After ethics approval and informed consent were obtained, a prospective trial was conducted. Patients with a symptomatic benign thyroid nodule were given a choice of HIFU treatment or active surveillance. Clinical and US examinations, pressure symptom scores (visual analog scale), and HRQOL questionnaires (short form-12 survey) were evaluated at baseline and at 3, 6, and 12 months. The primary outcome was change in nodule volume after 12 months. The percentage of change in nodule volume was defined as the baseline volume minus the volume at 12 months divided by the baseline volume times 100. Ablation success was defined as a reduction in volume of greater than 50%. Nodule volume was compared by using the paired t test. Continuous variables were compared by using the Mann-Whitney U test, and categorical variables were compared by using χ2 tests. Results Twenty-two patients underwent HIFU and 22 underwent active surveillance. Mean age was 53.11 years (range, 28-76 years) and 55.19 years (range, 41-70 years), respectively. The ratio of men to women was 2:20 and 1:21, respectively. The 12-month mean volume reduction ± standard deviation in the HIFU group was significant (68.87% ± 15.27 [range, 47.35%-94.89%], P < .001) but not in the surveillance group (-2.11% ± 6.29 [range, -15.64% to 12.70%], P > .05). Preablation nodule volume was the only determinant of ablation success (odds ratio, 1.877; 95% confidence interval [CI]: 1.085, 3.249; P = .024). At 12 months, patients in the HIFU group had less swelling (P < .001), lower pressure symptom scores (P < .001), and higher physical composite scores (P = .006). Physical composite scores significantly correlated with 6-month reduction in nodule size (r = 0.768; 95% CI: 0.660, 0.930; P < .001) and 12-month reduction in nodule size (r = 0.704; 95% CI: 0.680, 940; P < .001). Conclusion HIFU ablation of symptomatic benign thyroid nodules not only induced significant shrinkage but also improved pressure symptom scores and HRQOL throughout a 12-month period. © RSNA, 2017.
引用
- Lang BH, Woo YC, Wong CKH, et al. High-Intensity Focused Ultrasound for Treatment of Symptomatic Benign Thyroid Nodules: A Prospective Study. Radiology. 2017. PMID: 28419814. doi:10.1148/radiol.2017161640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。